Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2-3 trial.
Lancet HaematolSep 1, 2026
Clinical ResearchOncology (Medical)
Jeremy S Abramson, Susan Geyer, Sharmila Giri et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase 2-3 randomized controlled trial evaluated the efficacy of adding venetoclax to dose-adjusted EPOCH-R in patients with newly diagnosed double-hit lymphoma. The study included 73 patients aged 18-80 years. Results showed a median progression-free survival of 28.4 months for DA-EPOCH-R alone versus 7.7 months for the combination, with an early closure due to increased mortality in the venetoclax group.
Key findings
- Median progression-free survival was 28.4 months for DA-EPOCH-R versus 7.7 months for DA-EPOCH-R plus venetoclax.
- 24-month overall survival estimates were 72% for DA-EPOCH-R compared to 52% for the combination group.
- Early study closure was prompted by excess mortality in the DA-EPOCH-R plus venetoclax group.
Why it matters
The findings highlight the potential risks associated with adding venetoclax to standard therapy in double-hit lymphoma, emphasizing the need for careful consideration of treatment combinations in this aggressive malignancy.